Table 2 Description of participants’ age, gender, JIA categories, and treatment. Treatment is described at 12 months
Demographics | JASP-1, n = 56 | Control group, n = 26 |
|---|---|---|
Age range at diagnose (median) | 1–16 (10) | 1–16 (9.5) |
Gender | % (n) | % (n) |
Female | 64.3 (36) | 76.9 (20) |
Male | 35.7 (20) | 23.1 (6) |
JIA categories | ||
Polyarthritis RF pos | 10.7 (6) | 3.8 (1) |
Polyarthritis RF neg | 19.6 (11) | 19.2 (5) |
Oligoarthritis | 35.7 (20) | 30.8 (8) |
Psoriatic arthritis | 3.6 (2) | 3.8 (1) |
Enthesitis-related arthritis | 12.5 (7) | 0 |
Undifferentiated arthritis | 10 (17.9) | 34.6 (9) |
Treatment at 12 months | ||
No treatment* | 21.4 (12) | 19.2 (5) |
Methotrexate (MTX) | 25 (14) | 30.8 (8) |
Biologic | 8.9 (5) | 11.5 (3) |
MTX and biologic | 44.6 (25) | 38.5 (10) |